Lionel Hutz on Liquidia's patent battle $LQDA
Dec 19, 2022•1 hr 20 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Lionel Hutz discusses his thesis for Liquidia (LQDA) and why the thinks they are likely to win their patent battle against United Therapeutics (UTHR).
Lionel's LQDA write up: https://lionelhutz.substack.com/p/waiting-with-bated-breath-for-liquidia
Chapters
- 0:00 Intro
- 2:50 LQDA overview
- 8:05 Diving into the patent background
- 16:10 Breaking down the conflicting rulings on the '793 patent
- 19:55 Why the PTAB ruling is the most important for '793
- 21:55 What's so unique about the judge's ruling on '793
- 28:30 Why PTAB ruled the '793 patent invalid
- 37:40 LQDA's primary argument for invalidating '793
- 43:30 Discussing the expert reports around the '793 patent
- 53:30 Timeline to monetization and why delaying LQDA is so important for UTHR
- 59:00 LQDA's upside if they win
- 1:13:00 LQDA's cash runway
For the best experience, listen in Metacast app for iOS or Android